To test the hypothesis that early steroid pulsing augments the efficacy and decreases the toxicity of chrysotherapy 40 patients with rheumatoid arthritis were studied in a double blind, placebo controlled study. During the first three months of gold treatment group 1 received monthly intravenous methylprednisolone pulsing (steroid group) while group 2 received placebo (placebo group). All patients were assessed clinically and serologically over a 24 week period. Twelve patients were withdrawn before completion of the study and all but one of the remaining 28 patients reported clinical and serological improvements. Two patients in the steroid group were withdrawn owing to gold induced side effects while four were withdrawn in the placebo group. These small numbers were not significantly different. Minor side effects occurred more commonly in the placebo group. The clinical response was clearly better in the steroid group with statistical significance almost being achieved. In an endeavour to obtain a significant conclusion further patients will now be entered into this study.
Chrysotherapy has long been established as an effective treatment in suppressing disease activity in rheumatoid arthritis. Treatment is usually given as weekly intramuscular injection of gold salts. Most studies report useful therapeutic response in two thirds of patients, with 10-20% patients achieving almost complete remission generally apparent by the 12th week of treatment. ' The duration of suppressive response is variable. One third of patients receiving gold develop gold related side effects, however, and treatment is withdrawn in half of this population.' 2 Intravenous pulsing with large doses of methylprednisolone at monthly intervals has been shown to result in dramatic alleviation of articular symptoms in rheumatoid arthritis. 3 4 The duration of response is short lived, however, and does not significantly retard progression of the disease. This regimen has advantages over the continuous administration of oral steroids as serious side effects seem to be less common. During an open pilot study in which intravenous methylprednisolone pulsing was undertaken at the time of initiation of chrysotherapy we were impressed with the early clinical responses and the lack of gold related side effects in our group of rheumatoid patients.5
These observations raised the possibilities that steroid pulsing 'primed' the patients to respond to gold as well as reducing toxicity.
We report the results for 40 patients with active rheumatoid arthritis who were randomly allocated either to receive pulsed methylprednisolone and gold (sodium aurothiomalate) treatment (group 1) or pulsed placebo infusion and gold treatment (group 2). All patients were monitored clinically and with laboratory assessments.
Patients and methods Over a 27 month period 40 patients with classical or definite rheumatoid arthritis defined by American Rheumatism Association criteria were included in the study. All patients had active rheumatoid arthritis defined as more than three swollen joints, morning stiffness of greater than 45 minutes' duration, and a raised erythrocyte sedimentation rate or C reactive protein.
They had been treated with optimal doses of non-steroidal anti-inflammatory drugs and had moderate or marked restriction of function, thus justifying second line drug treatment.
Informed consent was obtained from all patients. There was no evidence of hepatic, haematological, or renal disease, and patients with insulin dependent diabetes mellitus were excluded.
All patients received intramuscular sodium aurothiomalate according to a standard protocol used in our department. The initial dose was 10 mg as a precaution for any immediate hypersensitivity reaction, the second dose was 20 mg given one week later, the third dose 50 mg in the third week, and thereafter 50 mg weekly. Treatment with non-steroidal anti-inflammatory drugs and analgesic drugs was continued unchanged throughout the study. Intra-articular corticosteroids were not permitted during the trial or within four weeks of entry into the trial.
These 40 patients were randomly allocated to either one of two groups.
Three intravenous pulses of I 0 g methylprednisolone in 100 ml normal saline were given over 30 minutes at time 0, 4, and 8 weeks to 20 patients in group 1, while 20 patients in group 2 received 100 ml saline infusion at the same intervals. These intravenous infusions were prepared by a pharmacist and both the patients and observer were unaware of the nature of the infusion. A second independent observer, who was aware of the nature of the infusion, assessed any potential drug toxicity by reviewing patients' progress at weeks 0, 1, 2, 3, 4, 6, 8, Wong, Champion, Smith, et al scores between groups 1 and 2 were compared a p value of 0-082 was obtained.
Discussion
Pulsed methylprednisolone has previously been shown by us and other investigators to produce rapid clinical improvements in patients with active rheumatoid arthritis, 6 though the improvement seems not to be sustained when pulsed methylprednisolone is used as the sole treatment. It has been shown to be associated with an early response (by at least six weeks) to the suppressive agents sulphasalazine and Dpenicillamine.6 To date there are few data to assess the efficacy and toxicity of combination pulse methylprednisolone and intramuscular gold v intramuscular gold alone. Anecdotal reports have suggested that intravenous pulse methylprednisolone decreased the efficacy of intramuscular gold treatment started at the time of the intravenous pulse. It has been suggested that the marked anti-inflammatory effects of corticosteroid treatment reduce bioavailability of gold salts to inflammatory cells in the synovium and synovial cavity. A recent paper, however, with limited number of patients, suggests beneficial effects of pulsed methylprednisolone in inducing an early remission before gold treatment becomes effective.7
Our data are consistent with our previous initial observations in a small number of patients that pulsed methylprednisolone combined with intramuscular gold treatment gives good symptomatic relief, but the results in this double blind, placebo controlled study just fail to reach a statistically significant level. Steroid treatment did not significantly alter the side effects either, but the numbers were too small for meaningful analysis. Overall, however, we are impressed with the relative lack of significant side effects from pulsed steroid treatment combined with chrysotherapy and the prompt and sustained clinical response. Consequently, we are enrolling further patients into the study in an effort to reach statistically significant conclusions. Furthermore, the knowledge that a large oral pulse of steroids gives similar clinical results to an intravenous pulse8 suggests that oral steroid pulsing combined with intramuscular gold will be a useful and convenient therapeutic option in patients with active rheumatoid arthritis. 
